TrialJournal of diabetes science and technology2021

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.

Liana K Billings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.